![]() |
| Breast cancer treatment |
Abu Dhabi is the first in the world to employ precision medicine to preempt advanced breast cancer with innovative treatment.
Abu Dhabi has cemented its leading position on the global medical innovation map, adding a new qualitative achievement to its health record, after becoming the first in the world to provide Camizestrant treatment for patients with advanced breast cancer, in a step that embodies the accelerating shift towards precision medicine based on proactive intervention, early detection and treatment tailored to the genetic characteristics of each patient.
This achievement comes under the supervision of the Department of Health – Abu Dhabi, where Burjeel Cancer Institute provided the innovative treatment to a patient in her forties who was diagnosed with advanced breast cancer, after tests revealed that she had a genetic mutation in the ESR1 gene, a mutation that is associated with the development of resistance to traditional hormonal treatments and contributes to the acceleration of its progression.
The medical team relied on an advanced technique for monitoring circulating tumor DNA (ctDNA), which allows for the detection of molecular changes associated with treatment resistance through the analysis of a blood sample, before any signs of disease progression appear through radiological imaging tests or clinical symptoms.
The new treatment represents a qualitative leap in the treatment of advanced breast cancer associated with this genetic mutation, as it allows for early therapeutic intervention before the appearance of clear signs of disease progression, which contributes to prolonging the period of control over it, delaying its development, and maintaining the quality of life of patients.
Her Excellency Dr. Noura Khamis Al Ghaithi, at the Department of Health – Abu Dhabi, said that the future of healthcare is no longer limited to treating disease after it appears, but is based on the ability to anticipate it and intervene early before it develops, stressing that providing the “Kamesstrant” treatment for the first time in the world from Abu Dhabi embodies the Emirate’s vision of building one of the smartest and most advanced health systems, based on prevention, early detection and harnessing the latest innovations to enable patients to access advanced treatments in a timely manner.
She added that the integration of advanced diagnostics, precision medicine and innovative treatments continues to raise the standards of healthcare in the emirate, contributing to improved health outcomes and enabling community members to enjoy better health and longer lives, and enhancing Abu Dhabi’s position as a leading global healthcare destination.
For his part, Professor Hamid Bin Harmal Al Shamsi, CEO of Burjeel Cancer Institute, said that the institute is proud to be the first center in the world to offer this innovative treatment within clinical practice, noting that this achievement reflects the institute’s vision of integrating advanced molecular diagnostics, artificial intelligence and modern analytical technologies within the patient care pathway, enabling more accurate and personalized treatment decisions according to the biological characteristics of each case.
He added that the achievement is not limited to providing a new drug, but embodies the adoption of an integrated model for precision oncology based on continuous molecular monitoring, where it has become possible through advanced ctDNA tests to detect very early resistance to hormonal treatment and to intervene before the appearance of any radiological or clinical signs of disease progression, which gives patients a greater chance to control the disease and maintain their quality of life.
This advanced therapeutic approach is based on the results of the global SERENA-6 study, which showed that converting patients with an ESR1 mutation detected via ctDNA testing to camisetrants treatment reduced the risk of disease progression or death by 56% compared to continuing with traditional hormone therapy.
The SERENA-6 study is the first global study to use sequential monitoring of circulating tumor DNA to guide treatment changes before clinical or radiological disease progression is detected, representing a fundamental shift in advanced breast cancer treatment methodologies and establishing a new phase of proactive therapeutic care.

0 Comments